Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

This study is testing a combination of two treatments — vusolimogene oderparepvec (VO), an oncolytic virus injected directly into tumors, and pembrolizumab, a standard immunotherapy drug — for people with cutaneous angiosarcoma, a rare and aggressive blood vessel cancer of the skin. The oncolytic virus is designed to infect and destroy tumor cells and stimulate the immune system. This combination approach aims to improve outcomes for patients whose cancer has progressed after previous immunotherapy. **You may be eligible if...** - You have confirmed cutaneous angiosarcoma that is locally advanced (cannot be removed by surgery) or has spread to other parts of the body - Your cancer has progressed after at least one prior immunotherapy-based treatment - You have at least one tumor that can be measured and injected directly - You have a life expectancy of at least 3 months - You have also received and progressed on standard chemotherapy (taxane or anthracycline-based) **You may NOT be eligible if...** - You have angiosarcoma of a type other than cutaneous (skin-based) - You have not yet tried prior immunotherapy or chemotherapy - You have an active autoimmune condition requiring treatment - You are immunocompromised or have HIV, hepatitis B, or hepatitis C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.